Lonza Group AG (LONN)
SIX Swiss Exchange · Switzerland · prices in CHF · close of 22 Oct 2026
Key indicators
| Last close | CHF 628.20 |
|---|---|
| 52-week range | 454.60 – 632.40 |
| Return, 1 month / 3 months | +11.6% / +17.1% |
| Return, 1 year / 3 years | +13.4% / +93.5% |
| Trend | Uptrend |
| RSI (14) | 73 |
| Volatility (1 year) | 22.7% |
| Worst drawdown (1 year) | -20.4% |
| Average daily value traded | 72.13M CHF |
| Dividend yield | 0.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Lonza Group is a Swiss company that works behind the scenes for the healthcare and life-science industries. It provides contract development and manufacturing services, helping pharmaceutical and biotechnology customers produce active ingredients, biologics and cell-based therapies. The company also supplies specialty chemical ingredients used in hygiene, personal care and other industrial applications. Lonza is based in Switzerland and serves customers around the world from manufacturing sites in several countries.
The shares are listed on the SIX Swiss Exchange in Switzerland under the code LONN, and the price on this page is in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Lonza Group AG (LONN) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 628.20 on 22 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 23 of 225 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 13.4% and over the last three months it rose 17.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 17.9% | ||
| From 52-week high | 0.0% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 17.1% | ||
| 6-month return | 24.9% | ||
| 12-month return, skipping the last month | 1.6% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 22.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.4% | ||
| Liquidity | 95 · Strong | Trades actively. | |
| Average daily value traded | 72.13M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.8% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.0% |
|---|---|
| 1 month | +11.6% |
| 3 months | +17.1% |
| 6 months | +24.9% |
| 1 year | +13.4% |
| 3 years | +93.5% |
| 5 years | −13.7% |
Signals
| 50-day / 200-day average | 573.43 / 533.01 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 13.25 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 May 2026 | CHF 5.0000 |
| 13 May 2025 | CHF 4.0000 |
| 13 May 2024 | CHF 4.0000 |
| 9 May 2023 | CHF 3.5000 |
| 9 May 2022 | CHF 3.0000 |
| 10 May 2021 | CHF 3.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.